News Sharing
For sharing news, please enter the email address of you and the receiver, then press SEND button.*Mandatory Fields
Receiver*
Enter email addresses, separated by semicolon (;). E.g. a@a.com;b@b.com
Your email address*
 Content Sharing
<Research>JPM: CN NRDL Adjustment to Accelerate Commercialization of Innovative Drugs; Top Picks INNOVENT BIO/ WUXI APPTEC/ WUXI XDC/ SKB BIO
China's National Healthcare Security Administration (NHSA) released the "Work Plan for the Adjustment of the 2026 National Reimbursement Drug List for Basic Medical Insura...
Reset
Send
The window will close in 5 seconds
<Research>JPM: CN NRDL Adjustment to Accelerate Commercialization of Innovative Drugs; Top Picks INNOVENT BIO/ WUXI APPTEC/ WUXI XDC/ SKB BIO
Close
Recommend
15
Positive
8
Negative
10
 
SHORT SELL
 
STOCK INFO
aacat by AASTOCKS
Open a new trading account to get Level 1 Real-Time Streaming!

China's National Healthcare Security Administration (NHSA) released the "Work Plan for the Adjustment of the 2026 National Reimbursement Drug List for Basic Medical Insurance, Maternity Insurance and Work Injury Insurance and the Innovative Drug List for Commercial Health Insurance (Draft for Consultation)", introducing multiple market-friendly rule changes. JP Morgan forecast the measures to further improve the commercial outlook for China's innovative drug developers and their CXO partners.

The most pivotal change is the first-time allowance for drugs to submit NRDL applications prior to formal approval, which is expected to sharply narrow the historical one- to two-year gap between drug approval and NRDL inclusion. In addition, the new plan formally establishes a linkage mechanism between commercial insurance and the national NRDL, creating a "commercial insurance coverage first, public insurance reimbursement later" model. This opens the door for high-priced innovative drugs that previously struggled to enter the NRDL due to pricing constraints.

Related NewsCiti: Fundamentals of China Healthcare Sector Continue to Improve; Top Picks WUXI APPTEC (02359.HK), WUXI BIO (02269.HK), ALI HEALTH (00241.HK)
The report pointed out that the formal establishment of a bridging pathway from commercial insurance to the NRDL validates the dual-list strategy long pursued by many innovative drug companies. For drugs currently covered by commercial insurance but not included in the NRDL - often because their retail prices previously exceeded the acceptable range in NRDL negotiations - the new rules are particularly meaningful.

The broker believed that clearer renewal rules will provide innovative drug companies with a more transparent long-term pricing roadmap, while the acceleration of innovative drug commercialization in China will directly benefit their CXO partners.

JP Morgan reiterated its positive view on INNOVENT BIO (01801.HK)  -1.650 (-1.860%)    Short selling $106.70M; Ratio 17.740%   , SKB BIO (06990.HK)  -8.400 (-1.823%)    Short selling $67.62M; Ratio 22.800%   , WUXI APPTEC (02359.HK)  +0.503 (+0.368%)    Short selling $122.45M; Ratio 20.510%   and WUXI XDC (02268.HK)  -0.700 (-1.236%)    Short selling $33.60M; Ratio 14.184%   , naming them as sector top picks.
(HK stocks quote is delayed for at least 15 mins.Short Selling Data as at 2026-05-13 16:25.)

Auto-translated by AI
View Original Text
This article was automatically translated by AI, the original language version should be considered the authoritative version. AASTOCKS.com Limited does not guarantee its accuracy or completeness and accepts no liability for any damages or losses arising from the use of this translation.

AASTOCKS Financial News
Copyright(C) AASTOCKS.com Limited 2000. All rights reserved.
Disclaimer: AASTOCKS.com Ltd, HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the Information provided but do not guarantee its accuracy or reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.